Abstract
The aggregation-prone Amyloid Beta (Aβ) peptide has been the target of the majority of efforts to develop Alzheimer’s Disease therapeutics, most of which have failed or have shown mixed results. Although clinical trials are ongoing, the failure of many efforts to slow or block pathogenesis by targeting Aβ over the past two decades calls for an urgent development of novel therapeutic concepts. In particular, the role of amyloid aggregation has come into question as it relates to Alzheimer's disease progression and it is no longer widely believed that buildup of amyloid fibrils in brain tissue is a causal factor in cognitive decline associated with the disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.